Janeta Popovici-Muller

Janeta is senior vice president, head of drug discovery, leading the advancement of Quotient’s programs from target identification to IND-enabled clinical candidates.

Janeta has more than two decades of experience in early and late-stage drug discovery within the biotech and pharmaceutical industry. Before joining Quotient, she served as head of drug design and advancement at WaveBreak, leading the discovery of small molecules targeting toxic intermediates production across neurodegenerative diseases. 

Prior roles include founding employee and SVP, head of drug discovery at Rectify Pharma, where she focused on disease-modifying precision therapies for ABC transporter mediated diseases, and VP, head of chemistry at Decibel Therapeutics. Earlier, Janeta co-led drug discovery programs at Agios Pharmaceuticals that delivered clinical-stage molecules in the areas of cancer metabolism (co-inventor of Tibsovo®) and rare genetic metabolic disorders (Pyrukynd®).

Before joining Agios, she spent 10 years at Merck Research Labs focused on small molecule drug discovery in oncology, inflammation, and anti-viral therapeutic areas. Janeta holds a PhD in organic chemistry from Dartmouth College.